The startup develops proprietary controlled release drug formulations to enhance medication adherence for patients with chronic diseases such as diabetes and cancer. By improving the pharmacokinetics of these drugs, the company aims to increase therapeutic efficacy and reduce the frequency of dosing.
Funding
Funding not disclosed
Founders
Product
Problem
Many existing medications require frequent dosing, leading to poor patient adherence, reduced therapeutic efficacy, and increased healthcare costs, especially for individuals managing chronic conditions. Traditional drug formulations often fail to maintain consistent drug concentrations in the body, resulting in fluctuating therapeutic effects.
Solution
G2GBIO develops innovative sustained-release drug formulations utilizing its proprietary InnoLAMP (Innovative Long-Acting MicroParticle) and InteLAMP technologies to address the challenges of medication adherence and pharmacokinetic variability. These technologies enable the creation of microparticle-based injectable drugs that provide consistent drug release over extended periods, ranging from one week to one month. By optimizing drug release profiles, G2GBIO aims to improve therapeutic outcomes, reduce dosing frequency, and enhance patient convenience. The company's InteLAMP technology further enhances efficacy by ensuring the released drug is evenly distributed within the target tissue, such as in tumor microenvironments.
Target Audience
The primary target audience includes pharmaceutical companies seeking to improve existing drug formulations, as well as healthcare providers and patients who would benefit from less frequent dosing schedules and improved medication adherence.
Features
- InnoLAMP technology for controlled release of drugs via injectable microparticles
- InteLAMP technology for enhanced drug distribution within target tissues
- Development of long-acting injectable formulations for various therapeutic areas, including diabetes, Alzheimer's disease, and pain management
- GMP-certified manufacturing facilities for clinical trial material production
- Pipeline includes a one-month semaglutide formulation (GB-7001) and a one-month donepezil formulation (GB-5001)
- Expertise in developing microparticle manufacturing processes suitable for mass production